Clinical Updates

COVID-19 vaccines spread hope as Cigna helps spread the word

Cigna welcomes and encourages the use of available COVID-19 vaccines authorized by the U.S. Food and Drug Administration (FDA).

Read more

Proven success to help lower A1C levels for patients with diabetes

As part of our SafeGuardRx® for Cigna program, Cigna provides one-on-one drug adherence counseling and support that’s proven to help lower A1C levels. When engaging with a Cigna coach through this program, 63% of those with an A1C level of 8 or above were able to lower their A1C levels to a goal of less than 8.

Read more

Cigna is closely monitoring the Coronavirus (COVID-19) outbreak

Our top priority is to protect the health and well-being of our clients, customers and our employees and their families. We have put together resources, information, and helpful links on Cigna.com to keep you up-to-date and informed.

Read more

New migraine drugs approved by FDA

The United States Food and Drug Administration (FDA) recently approved three new drugs (Nurtec™ ODT, Reyvow™, and Ubrelvy™) for the acute treatment of migraine headaches and one new drug for the prevention of migraine headaches (Vyepti™).  

Read more

Vyleesi™ approved to treat HSDD in premenopausal women

Vyleesi (bremelanotide) is considered a sexual dysfunction drug and is the first specialty drug in this category. It is the second drug approved by the U.S. Food and Drug Administration (FDA) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

Read more

New checkpoint helps opioid users after a medical emergency

The issues of opioid misuse and overdose don’t stop, so we won’t stop either. A new outreach effort works to identify and reach out to opioid users with a recently detected medical emergency. Our goal is to help lead them to beneficial resources that might reduce their risk for overdose.

Read more

Cigna pioneers solution for life-changing therapies

Cigna Health Services Business announces a significant new way we’re advancing healthcare. We are proud to introduce Embarc Benefit ProtectionSM, the industry’s first solution to begin to address the high cost of certain potentially curative gene therapy medicines.

Read more

Reducing opioid use with the help of integrated dental, medical and pharmacy data

As part of a long-standing commitment to help curb opioid addiction and overdose, Cigna has collaborated with dentists to increase awareness of the dangers of opioids, the greater risk of misuse and addiction among teenagers, and safer non-opioid options to manage acute dental pain.

Read more

Customers new to opioids get safer start

Drug abuse can become ongoing and compulsive. In fact, it only takes 10 days. With just a 10-day prescription, one in five people have an increased risk of opioid addiction. The Cigna Safe Opioid Starts (SOS) program attempts to help prevent this tough situation from taking root.

Read more

Enhanced Narcotic Therapy Management Program working to identify opioid risks

In March 2018, Cigna reached its goal of reducing opioid use by 25% among our commercial customer base – one year ahead of schedule. But our work will continue, as we work toward another milestone in reducing overdose among members.

Read more

Keeping mental health research and response top of mind

The Coronavirus pandemic continues to tug at our society’s collective mental state with its unrelenting demands: maintaining distance from others, wearing of masks, being more thoughtful than ever before about sanitizing measures, and so on. We recognize that this new and often tiring circumstance calls for increased behavioral health support. 

Read more

How we address biosimilar products today

It is one of our ongoing goals to reduce drug spend and improve health. As part of these efforts, we evaluate new biosimilar products individually as they come to market. A biosimilar is a biological product highly similar to an existing U.S. Food and Drug Administration (FDA) – approved reference product.

Read more

New treatment for infants with spinal muscular atrophy

On May 24, 2019, the U.S. Food and Drug Administration approved Zolgensma (onasemnogene abeparvovec), a new gene replacement therapy. Zolgensma is approved to treat children less than two years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene, a leading genetic cause of infant mortality.

Read more

First peanut allergy treatment approved by FDA

A first-of-its-kind treatment for patients with peanut allergy is now available. The U.S. Food and Drug Administration (FDA) announced approval of Palforzia®, by the manufacturer Aimmune Therapeutics, Inc., as of January 31, 2020.

Read more

Lyrica loses patent protection, generics now available

Lyrica is commonly used to treat pain caused by nerve damage due to diabetes, shingles (herpes zoster) infection, fibromyalgia or spinal cord injury. It is also used with other medications to treat certain types of seizures.

Read more

Entresto PA removal tied to Cigna’s formulary strategy

As of November 15, 2018, Cigna has removed the prior authorization (PA) requirement for Entresto, a drug used to reduce the risk of cardiovascular death and hospitalizations for patients with chronic heart failure.

Read more

Legal Disclaimer | Privacy | Product Disclosures | Cigna Company Names

Product availability may vary by location and plan type and is subject to change. All group health insurance policies and health benefit plans contain exclusions and limitations. For costs and details of coverage, review your plan documents or contact a Cigna representative.

All Cigna products and service are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, (CHLIC), Evernorth Care Solutions, Inc., Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., Evernorth, Accredo Health Group, Inc., Express Scripts, Inc., ESI Mail Pharmacy Service, Inc., Express Scripts Pharmacy, Inc., Tel-Drug, Inc., Tel-Drug of Pennsylvania, L.L.C., Lynnfield Drug, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. Policy forms: OK - HP-APP-1 et al., OR - HP-POL38 02-13, TN - HP-POL43/HC-CER1V1 et al. (CHLIC). The Cigna name, logo, and other Cigna marks are trademarks of Cigna Intellectual Property, Inc. "Express Scripts" is a trademark of Express Scripts Strategic Development, Inc. This newsletter is not intended for residents of New Mexico.

© 2021 Cigna. All rights reserved